Objective: Cytodiagnoses of specific malignancies are enabled through analyses of abnormal nuclear chromatin and cytoplasmic features in stained cells. Aim: The objective of this work was to explore the inception, development, and chemistry of the Pap stain method introduced in 1942 by Dr. G.N. Papanicolaou. Study Design: To achieve this, we carried out a review of the English literature. Results: Between 1914 and 1933, Papanicolaou first analyzed vaginal squamous cells in guinea pigs and later in human vaginal fluid samples using hematoxylin and eosin with limited color reactions, correlating the cell-type morphology with endocrinology and histology. The 5-dye Pap stain method evolved through 2 salient phases. The first, between 1933 and 1942, saw the introduction of alcohol-ether fixation and aqueous waterblue staining to enhance cellular transparency, aiding the distinction of cervical cancer cells from benign cells, with quantitative and qualitative assessment of squamous cell maturity. The second phase, between 1942 and 1960, saw the introduction and refinement of various alcoholic cytoplasmic counterstaining schemes with orange G and EA (light green, Bismarck brown, eosin) and phosphotungstic acid, allowing wider ranges of polychromasia and further enhancing cellular visualization, facilitating the distinction of cell types and improving diagnostic confidence. Conclusions: Development of the Pap stain method followed specific historical and scientific events. The staining method evolved following incremental improvements in cellular transparency achieved through tailored cellular fixation and cytoplasmic staining using variable dye and pH combinations.

Keywords:
Vaginal fluid smear, Papanicolaou stain, Pap stain, Cornification, Fixation, Pap test
1.
Papanicolaou GN: A new procedure for staining vaginal smears. Science 1942;95:438-439.
2.
Boon ME, Chantziantoniou N: Papanicolaou Revisited. Leyden, Coulomb, 2013.
3.
Boon ME, Drijver JS: Routine Cytological Staining Techniques. London, MacMillan Education, 1986.
4.
Gill GW: Cytopreparation - Principles and Practice. New York, Springer, 2013.
5.
Papanicolaou GN: The sexual cycle in the human female as revealed by vaginal smears. Am J Anat 1933;52:519-637.
6.
Papanicolaou GN, Traut HF: Diagnosis of Uterine Cancer by the Vaginal Smear. New York, The Commonwealth Fund, 1943.
7.
Papanicolaou GN: Atlas of Exfoliative Cytology. New York, The Commonwealth Fund, Harvard University Press, 1954.
8.
Carmichael DE: The Pap Smear - Life of George N. Papanicolaou. Springfield, Charles Thomas, 1973.
9.
Chantziantoniou N: The wars against cervical cancer. JASC 2014;3:275-279.
10.
Chantziantoniou N: The Pap test - celebrating 100 years in the making and beyond. JASC 2014;3:143-150.
11.
Chantziantoniou N: Lady Andromache (Mary) Papanicolaou: the soul of gynecological cytopathology. JASC 2014;3:319-326.
12.
Traut HF: Necrologia: Obituary for George N. Papanicolaou, MD, PhD. Oncology 1963;16:351-353.
13.
Stockard CR, Papanicolaou GN: A rhythmical ‘heat period' in guinea pigs. Science 1917;46:42-44.
14.
Stockard CR, Papanicolaou GN: The existence of a typical oestrous cycle in the guinea-pig - with a study of its histological and physiological changes. Am J Anat 1917;22:225-283.
15.
Austin RM, Chantziantoniou N: George Nicholas Papanicolaou: the unlikely story of an intellectual immigrant; one driven to contribute on a large stage; one who finally succeeded by scientifically inspiring numerous cooperating individuals and organizations. JASC 2014;3:331-334.
16.
Papanicolaou GN: Diagnosis of early human pregnancy by the vaginal smear method. Proc Soc Exp Biol Med 1925;22:436-437.
17.
Papanicolaou GN: New cancer diagnosis; in: Proceedings of the Third Race Betterment Conference. Battle Creek, Race Betterment Foundation, 1928, pp 528-534.
18.
Koss LG: Papanicolaou's 100th birthday. Acta Cytol 1983;27:217-219.
19.
Papanicolaou GN, Shorr E: The action of ovarian follicular hormones in the menopause, as indicated by vaginal smears. Am J Obstet Gynecol 1936;31:806-831.
20.
Turnock BJ: Public Health - What It Is and How It Works. Burlington, Jones & Bartlett Learning, 2012.
21.
Papanicolaou GN, Traut HF: The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;42:193-206.
22.
Papanicolaou GN, Traut HF: Cancer cells in vaginal smears. Anat Rec 1942;82:488.
23.
Papanicolaou GN, Traut HF: The demonstration of malignant cells in vaginal smears and its relation to the diagnosis of carcinoma of the uterus. NY State J Med 1943;43:767-768.
24.
Naylor B: The century for cytopathology. Acta Cytol 2000;44:709-725.
25.
Meigs JV: The vaginal smear - practical applications in the diagnosis of cancer of the uterus. J Am Med Assoc 1947;133:75-78.
26.
Lindsay S: The Papanicolaou-Traut method of cancer diagnosis - its use as a routine pathologic laboratory procedure. Calif Med 1949;70:413-416.
27.
Papanicolaou GN: The cell smear method of diagnosing cancer. Am J Public Health Nations Health 1948;38:202-205.
28.
Papanicolaou GN: Some improved methods for staining vaginal smears. J Lab Clin Med 1941;26:1200-1205.
29.
Boon ME: Routine cytologic staining procedures; in Wied GL, Keebler CM, Koss LG, Reagan JW (eds): Compendium on Diagnostic Cytology, ed 6. Chicago, Tutorials of Cytology (IAC), 1990, pp 579-584.
30.
Papanicolaou GN: Historical development of cytology as a tool in clinical medicine and in cancer research. Acta Unio Int Contra Cancrum 1958;14:249-254.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.